NDA 208716 · Eli Lilly and CO
Verzenio
Abemaciclib · Oral · Kinase Inhibitor
NovelBreakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Sep 28, 2017
Approved uses
10
Original approval plus efficacy supplements
Registered trials
248
32 Phase 3, 85 recruiting
FAERS reports
21,145
10,932 serious, 1,481 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 18, 2026.
VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) in combination with imlunestrant for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. ( 1.2 , 2.1 ) as monotherapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. 1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or...
Mechanism: Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 18, 2026 Supplement 22 · Efficacy LabelLetter
- Jul 13, 2026 Supplement 21 · Efficacy LabelLetter
- Nov 13, 2024 Supplement 17 · Efficacy LabelLetter
- Mar 3, 2023 Supplement 11 · Efficacy LabelLetter
- Mar 3, 2023 Supplement 10 · Efficacy LabelLetter
- Oct 12, 2021 Supplement 8 · Efficacy LabelLetter
- Oct 12, 2021 Supplement 6 · Efficacy LabelLetter
- Oct 12, 2021 Supplement 7 · Efficacy LabelLetter
- Mar 30, 2020 Supplement 4 · Efficacy LabelLetter
- Sep 28, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
4 products under this application
- VERZENIO · ABEMACICLIB 200MG · TABLET, ORAL · Prescription
- VERZENIO · ABEMACICLIB 100MG · TABLET, ORAL · Prescription
- VERZENIO · ABEMACICLIB 150MG · TABLET, ORAL · Prescription
- VERZENIO · ABEMACICLIB 50MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Abemaciclib" as an intervention, any sponsor and status, largest first.
- Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT03155997 · 5,637 participants · Start Jul 12, 2017 · Primary completion Mar 16, 2020
Drug: Abemaciclib; Standard Adjuvant Endocrine Therapy · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Gilbert, Arizona · 619 sites in all
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05952557 · 5,511 participants · Start Oct 5, 2023 · Primary completion Mar 4, 2030
Drug: Camizestrant; Tamoxifen and 4 more · For: Breast Cancer, Early Breast Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 661 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
- Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant AbemaciclibPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT06341621 · 1,900 participants (planned) · Start Apr 2, 2024 · Primary completion Feb 25, 2027
Drug: 3-year abemaciclib without chemo; treatment of physician's choice · For: Breast Cancer
Sites: Shanghai, China
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBCPivotal-lookingActive, not recruiting
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT04565054 · 1,260 participants (planned) · Start Sep 2, 2020 · Primary completion Jun 2028
Drug: Abemaciclib 50 MG; 150mg 1-0-1 per os · For: Breast Cancer Female
Sites: Freiburg im Breisgau, Germany; Heilbronn, Germany; Ravensburg, Germany · 85 sites in all
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07005557 · 1,244 participants (planned) · Start Jun 15, 2025 · Primary completion May 15, 2030
Drug: Chemotherapy; CDK4/6 Inhibitor and 1 more · For: Breast Cancer; Adjuvant Therapy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea6,577
- fatigue2,834
- nausea2,345
- vomiting1,196
- malignant neoplasm progression1,148
- decreased appetite1,021
- asthenia941
- death811
- constipation767
- white blood cell count decreased761
- drug ineffective752
- abdominal pain upper735
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 25 |
| 2018 | 850 |
| 2019 | 1,657 |
| 2020 | 1,648 |
| 2021 | 1,496 |
| 2022 | 2,192 |
| 2023 | 2,788 |
| 2024 | 3,399 |
| 2025 | 3,735 |
| 2026 | 3,345 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Verzenio (Abemaciclib)
2024 spending
$1.06B
Beneficiaries
11,239
71,933 claims
Per beneficiary
$94,026
$268.49 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $286,188,073 |
| 2021 | $324,570,465 |
| 2022 | $474,171,738 |
| 2023 | $756,850,867 |
| 2024 | $1,056,757,309 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Johnston SRD, Harbeck N, Hegg R, et al. · J Clin Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
Jhaveri KL, Neven P, Casalnuovo ML, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
Bidard FC, Mayer EL, Park YH, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP, Toi M, Campone M, et al. · J Clin Oncol 2017 · Clinical Trial, Phase III, Multicenter Study
- Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.
Kalinsky K, Bianchini G, Hamilton E, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD, Toi M, O'Shaughnessy J, et al. · Lancet Oncol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.